# A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

> **NCT03669718** · PHASE2 · UNKNOWN · sponsor: **ISA Pharmaceuticals** · enrollment: 194 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of the Oropharynx
- HPV16 Positive

## Interventions

- **BIOLOGICAL:** ISA101b
- **DRUG:** Cemiplimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03669718
- **Lead sponsor:** ISA Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-30
- **Primary completion:** 2024-09
- **Final completion:** 2025-06
- **Target enrollment:** 194 (ESTIMATED)
- **Last updated:** 2023-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03669718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03669718, "A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03669718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*